What is the history of Pallister-Killian Syndrome / Tetrasomy 12p?

Pallister-Killian Syndrome (PKS), also known as Tetrasomy 12p, is a rare genetic condition first described in the late 1970s and early 1980s, characterized by the presence of an extra isochromosome 12p in some, but not all, of the body's cells. This condition, which arises from mosaicism, has evolved from a clinical mystery to a condition now identifiable through advanced molecular diagnostic techniques.

When and how was Pallister-Killian Syndrome first described?

The clinical features of Pallister-Killian Syndrome were first detailed by Philip Pallister in 1977, followed by Maria Teschler-Nicola and Wolfgang Killian in 1981. Initially, it was referred to as "mosaic tetrasomy 12p" because the extra genetic material is only present in a subset of cells, often disappearing from blood cells over time, which historically made diagnosis extremely challenging.

How has our understanding of Tetrasomy 12p evolved?

Early researchers struggled to identify Pallister-Killian Syndrome because standard blood karyotyping often failed to detect the extra chromosome. The medical community eventually learned that the abnormal cells are often restricted to skin fibroblasts or other tissues, rather than circulating blood. Modern genetic advancements, such as microarray analysis and specialized skin biopsy testing, have revolutionized our ability to confirm a diagnosis of Pallister-Killian Syndrome.

What historical milestones define the history of this condition?

Understanding the history of Pallister-Killian Syndrome involves several key milestones in clinical genetics:

• 1977: Philip Pallister provides the first clinical report of the syndrome.


• 1981: Killian and Teschler-Nicola clarify the cytogenetic nature of the condition.


• 1985: The term "Pallister-Killian Syndrome" becomes widely adopted in medical literature.


• 2000s: The widespread implementation of chromosomal microarray (CMA) technology allows for faster and more accurate detection of the mosaic tetrasomy 12p.

How has patient advocacy changed the landscape?

In the early days, families affected by Pallister-Killian Syndrome often faced isolation due to the rarity of the diagnosis. Today, organizations and platforms like DiseaseMaps.org connect families, including the 9 community members who have shared their experiences. This collective advocacy has shifted the focus from mere identification to improving the quality of life for those living with Pallister-Killian Syndrome through interdisciplinary supportive care.

Next steps

• Consult a clinical geneticist to discuss the most accurate diagnostic testing for Pallister-Killian Syndrome, such as skin biopsy-based chromosomal analysis.


• Connect with the DiseaseMaps.org community to share experiences and learn from other families navigating this diagnosis.


• Work with a multidisciplinary team including neurologists, speech therapists, and physical therapists to manage the specific needs of your loved one.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH GARD (Genetic and Rare Diseases Information Center): Pallister-Killian syndrome.


• Orphanet: Pallister-Killian syndrome (ORPHA:680).


• OMIM (Online Mendelian Inheritance in Man): Pallister-Killian Mosaic Syndrome (Entry #601803).


• Pallister-Killian Syndrome Foundation: Patient advocacy and research resources.